Development and applications of oncolytic Maraba virus vaccines

References

• PolJKroemerGGalluzziLFirst oncolytic virus approved for melanoma immunotherapyOncoimmunology201651e111564126942095
   PubMed Web of Science ®Google Scholar
• Travassos da RosaAPTeshRBTravassos da RosaJFHerveJPMainAJJrCarajas and Maraba viruses, two new vesiculoviruses isolated from phlebotomine sand flies in BrazilAm J Trop Med Hyg198433599910066091472
   PubMed Web of Science ®Google Scholar
• BrunJMcManusDLefebvreCIdentification of genetically modified Maraba virus as an oncolytic rhabdovirusMol Ther20101881440144920551913
   PubMed Web of Science ®Google Scholar
• JohnsonJENasarFColemanJWNeurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primatesVirology20073601364917098273
   PubMed Web of Science ®Google Scholar
• PolJGRességuierJLichtyBDOncolytic viruses: a step into cancer immunotherapyVirus Adapt Treat201141121
   Google Scholar
• PolJGLévesqueSWorkenheSTTrial Watch: oncolytic viro-immunotherapy of hematologic and solid tumorsOncoImmunology2018132
   Web of Science ®Google Scholar
• PolJBuquéAArandaFTrial Watch-Oncolytic viruses and cancer therapyOncoimmunology201652e111774027057469
   PubMed Web of Science ®Google Scholar
• PolJBloyNObristFTrial Watch:: Oncolytic viruses for cancer therapyOncoimmunology20143e2869425097804
   PubMed Web of Science ®Google Scholar
• BreitbachCJLichtyBDBellJCOncolytic Viruses: Therapeutics With an Identity CrisisEBioMedicine20169313627407036
   PubMed Web of Science ®Google Scholar
• StojdlDFAbrahamNKnowlesSThe murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virusJ Virol200074209580958511000229
   PubMed Web of Science ®Google Scholar
• StojdlDFLichtyBKnowlesSExploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virusNat Med20006782182510888934
   PubMed Web of Science ®Google Scholar
• StojdlDFLichtyBDTenoeverBRVSV strains with defects in their ability to shutdown innate immunity are potent systemic anticancer agentsCancer Cell20034426327514585354
   PubMed Web of Science ®Google Scholar
• LichtyBDPowerATStojdlDFBellJCVesicular stomatitis virus: re-inventing the bulletTrends Mol Med200410521021615121047
   PubMed Web of Science ®Google Scholar
• LichtyBDStojdlDFTaylorRAVesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancyHum Gene Ther200415982183115353037
   PubMed Web of Science ®Google Scholar
• TongJGValdesYRBarrettJWEvidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasisMol Ther Oncolytics201521501327119108
   PubMed Web of Science ®Google Scholar
• TongJGValdesYRSivapragasamMSpatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potentialBMC Cancer201717159428854921
   PubMed Web of Science ®Google Scholar
• Le BoeufFSelmanMSonHHOncolytic Maraba Virus MG1 as a Treatment for SarcomaInt J Cancer201714161257126428568891
   PubMed Web of Science ®Google Scholar
• AthertonMJStephensonKBPolJCustomized Viral Immunotherapy for HPV-Associated CancerCancer Immunol Res201751084785928912369
   PubMed Web of Science ®Google Scholar
• Bourgeois-DaigneaultMCSt-GermainLERoyDGCombination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatmentBreast Cancer Res20161818327503504
   PubMed Web of Science ®Google Scholar
• PolJGZhangLBridleBWMaraba virus as a potent oncolytic vaccine vectorMol Ther201422242042924322333
   PubMed Web of Science ®Google Scholar
• Bourgeois-DaigneaultMCRoyDGAitkenASNeoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapySci Transl Med201810422eaao164129298865
   PubMed Web of Science ®Google Scholar
• MahoneyDJLefebvreCAllanKVirus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell deathCancer Cell201120444345622014571
   PubMed Web of Science ®Google Scholar
• AlkayyalAATaiLHKennedyMANK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular VaccineCancer Immunol Res20175321122128159747
   PubMed Web of Science ®Google Scholar
• ConradDPTsangJMacleanMLeukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemiaClin Cancer Res201319143832384323714728
   PubMed Web of Science ®Google Scholar
• AthertonMJStephensonKBTzelepisFTransforming the prostatic tumor microenvironment with oncolytic virotherapyOncoimmunology201877e144545929900060
   PubMed Web of Science ®Google Scholar
• AthertonMJStephensonKBNikotaJKPreclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancerVaccine201836162181219229544689
   PubMed Web of Science ®Google Scholar
• ZhangJTaiLHIlkowCSMaraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseMol Ther20142271320133224695102
   PubMed Web of Science ®Google Scholar
• AitkenASRoyDGMartinNTSadSBellJCBourgeois-DaigneaultMCBrief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in MiceJ Immunother201841312512929293165
   PubMed Web of Science ®Google Scholar
• KimREffects of surgery and anesthetic choice on immunosuppression and cancer recurrenceJ Transl Med2018161829347949
   PubMed Web of Science ®Google Scholar
• GujarSPolJGKimYLeePWKroemerGAntitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Viro-therapiesTrends Immunol201839320922129275092
   PubMed Web of Science ®Google Scholar
• GujarSPolJGKroemerGHeating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapiesOncoimmunology201878e144216930221036
   PubMed Web of Science ®Google Scholar
• CroxfordALKuligPBecherBIL-12-and IL-23 in health and diseaseCytokine Growth Factor Rev201425441542125130295
   PubMed Web of Science ®Google Scholar
• HummelJBienzleDMorrisonAMaraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for catsSci Rep201771573829146945
   PubMed Web of Science ®Google Scholar
• BoisgeraultNKottkeTPulidoJFunctional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapseMol Ther20132181507151623752316
   PubMed Web of Science ®Google Scholar
• BridleBWBoudreauJELichtyBDVesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirusMol Ther200917101814182119603003
   PubMed Web of Science ®Google Scholar
• BridleBWChenLLemayCGHDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapyMol Ther201321488789423295947
   PubMed Web of Science ®Google Scholar
• BridleBWClouthierDZhangLOncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccinesOncoimmunology201328e2601324083086
   PubMed Web of Science ®Google Scholar
• BridleBWNguyenASalemOPrivileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost VaccinationJ Immunol2016196114587459527183620
   PubMed Web of Science ®Google Scholar
• BridleBWStephensonKBBoudreauJEPotentiating cancer immunotherapy using an oncolytic virusMol Ther20101881430143920551919
   PubMed Web of Science ®Google Scholar
• KottkeTErringtonFPulidoJBroad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsNat Med201117785485921685898
   PubMed Web of Science ®Google Scholar
• PulidoJKottkeTThompsonJUsing virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanomaNat Biotechnol201230433734322426030
   PubMed Web of Science ®Google Scholar
• RommelfangerDMWongthidaPDiazRMSystemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transferCancer Res201272184753476422836753
   PubMed Web of Science ®Google Scholar
• LedgerwoodJEZephirKHuZVRC 310 Study TeamPrime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effectJ Infect Dis2013208341842223633407
   PubMed Web of Science ®Google Scholar
• ZhangLBridleBWChenLDelivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responsesBlood2013121132432243923325836
   PubMed Web of Science ®Google Scholar
• PolJGAcunaSAYadollahiBPreclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trialsOncoimmunology201877115
   Google Scholar
• YuanHChenVBoisvertMIsaacsCGlazerRIPLAC1 as a serum biomarker for breast cancerPLoS One2018132e019210629432428
   PubMed Web of Science ®Google Scholar
• DrakeCGLipsonEJBrahmerJRBreathing new life into immuno-therapy: review of melanoma, lung and kidney cancerNat Rev Clin Oncol2014111243724247168
   PubMed Web of Science ®Google Scholar
• GjerstorffMFAndersenMHDitzelHJOncogenic cancer/testis antigens: prime candidates for immunotherapyOncotarget2015618157721578726158218
   PubMedGoogle Scholar
• JonkerDJHotteSJAbdul RazakARPhase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214J Clin Oncol20173515 Supple14637
   Web of Science ®Google Scholar
• ReinaMEspelERole of LFA-1 and ICAM-1 in CancerCancers (Basel)2017911E15329099772
   PubMed Web of Science ®Google Scholar
• FujiwaraTShirakawaYKagawaSTelomerase-specific oncolytic virotherapy for human gastrointestinal cancerExpert Rev Anticancer Ther201111452553221504319
   PubMed Web of Science ®Google Scholar
• PrestwichRJIlettEJErringtonFImmune-mediated anti-tumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replicationClin Cancer Res200915134374438119509134
   PubMed Web of Science ®Google Scholar
• MorganRAChinnasamyNAbate-DagaDCancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapyJ Immunother201336213315123377668
   PubMed Web of Science ®Google Scholar
• CameronBJGerryABDukesJIdentification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cellsSci Transl Med20135197ra03
   Web of Science ®Google Scholar
• LinetteGPStadtmauerEAMausMVCardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaBlood2013122686387123770775
   PubMed Web of Science ®Google Scholar
• de GraafJFde VorLFouchierRAMvan den HoogenBGArmed oncolytic viruses: A kick-start for anti-tumor immunityCytokine Growth Factor Rev201841283929576283
   PubMed Web of Science ®Google Scholar
• HirvinenMCapassoCGuseKExpression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunityMol Ther Oncolytics201631600227626058
   PubMed Web of Science ®Google Scholar
• GalluzziLBuquéAKeppOZitvogelLKroemerGImmunogenic cell death in cancer and infectious diseaseNat Rev Immunol20171729711127748397
   PubMed Web of Science ®Google Scholar
• van VlotenJPWorkenheSTWoottonSKMossmanKLBridleBWCritical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination ImmunotherapiesJ Immunol2018200245045829311387
   PubMed Web of Science ®Google Scholar
• MiyamotoSInoueHNakamuraTCoxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinomaCancer Res201272102609262122461509
   PubMed Web of Science ®Google Scholar
• DiaconuICerulloVHirvinenMLImmune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirusCancer Res20127292327233822396493
   PubMed Web of Science ®Google Scholar